In the evolving landscape of vaccine technology, mRNA and lipid nanoparticle (LNP) platforms have revolutionized our approach to immunization, particularly with the development of vaccines against SARS-CoV-2. These novel vaccines function by delivering mRNA sequences encoding specific protein antigens into host cells, thereby inducing in vivo antigen production, which in turn stimulates adaptive immune responses including both B cells and T cells. While it is well-established that B cells can be activated directly through the recognition of these protein antigens, the mechanisms steering T cell activation, particularly CD8+ cytotoxic T lymphocytes (CTLs), remain incompletely understood within the context of mRNA–LNP vaccination.
Historically, activation of CD8+ T cells necessitates antigen processing and presentation by major histocompatibility complex class I (MHC-I) molecules on antigen-presenting cells (APCs). Conventional dendritic cells type 1 (cDC1s) have been recognized as pivotal players in cross-presentation — a process whereby exogenous antigens are presented on MHC-I molecules — which is critical for cytotoxic T cell priming in viral infections, tumor immunity, and with certain vaccine modalities such as protein- and cDNA-based vaccines. Despite this, the precise role of cDC1 cells and the associated cross-presentation machinery in the context of mRNA–LNP vaccines had not been firmly established, prompting a detailed investigation in this latest study led by Jo, Li, Thakur, and colleagues.
The researchers provide compelling evidence that, contrary to prior assumptions, effective CD8+ T cell priming following mRNA–LNP vaccination does not solely depend on cDC1 cells or the canonical WDFY4-dependent cross-presentation pathway. Utilizing genetically engineered mouse models deficient in cDC1 cells and components essential for classical cross-presentation, the team demonstrated that CD8+ T cell responses were maintained. This indicates a redundancy in dendritic cell subsets capable of instigating cytotoxic T cell immunity, thus broadening the understanding of APC roles in response to mRNA vaccines.
One of the pivotal findings is that both cDC1 and cDC2 dendritic cell subsets can independently prime CD8+ T cells, suggesting a level of functional plasticity that can compensate for the absence of one subset. Crucially, though these individually primed CD8+ T cells exhibited distinct phenotypic characteristics, both subsets were capable of mediating potent anti-tumor immunity and the formation of immunological memory. This finding has profound implications for vaccine design, highlighting the resilience and adaptability of cellular immune responses elicited by mRNA–LNP platforms.
Delving further into the mechanisms underlying these observations, the study uncovers the significant role of a process known as “cross-dressing,” wherein cDCs acquire peptide–MHC-I complexes directly from non-hematopoietic cells. This alternative pathway of antigen presentation substantially contributes to the priming of CD8+ T cells during mRNA vaccination. Notably, the effectiveness of cross-dressing relies on type I interferon signaling, a critical component of the innate immune response that enhances the ability of dendritic cells to stimulate T cell responses.
This discovery sheds light on why mRNA–LNP vaccines can potently activate CD8+ T cells against antigens that may not be directly encoded by the vaccine itself, a phenomenon that could not be easily explained by classical antigen presentation pathways alone. The induction of cross-dressing by mRNA vaccines potentially broadens the spectrum of antigen targets, implying that these vaccines might harness unconventional but highly efficient immune activation routes.
Importantly, the study’s insights challenge and expand the current paradigms of immune activation by nucleic acid vaccines. By demonstrating that mRNA–LNP vaccines bypass strict reliance on cDC1 and cross-presentation, the research opens avenues for optimizing vaccine formulations to exploit multiple dendritic cell subsets and innate immune pathways, potentially enhancing the breadth, potency, and durability of CD8+ T cell responses.
The broader implications extend to cancer immunotherapy, where robust and durable cytotoxic T cell responses are critical for tumor clearance. The ability of mRNA vaccines to stimulate CD8+ T cells through unconventional dendritic cell activation pathways may translate into improved strategies for cancer vaccine development. Moreover, understanding the role of cross-dressing could inform approaches to circumvent immune evasion mechanisms employed by tumors or persistent viral infections.
From a mechanistic perspective, the study also underscores the intricate interplay between innate signaling pathways, such as type I interferon, and antigen presentation processes. Type I interferons appear to orchestrate the acquisition of peptide–MHC-I complexes by dendritic cells, reinforcing the notion that successful vaccine-induced immunity depends on finely-tuned coordination between innate and adaptive immune components.
The findings encourage revisiting the design of adjuvants and delivery systems within mRNA vaccines to harness or amplify these unconventional pathways. Tailoring vaccine constructs to promote enhanced cross-dressing and engagement of both cDC1 and cDC2 subsets could yield more potent and broadly effective vaccines, not only against infectious diseases but also in immuno-oncology.
In summary, the research led by Jo et al. reveals an unexpected flexibility in dendritic cell-mediated CD8+ T cell priming by mRNA–LNP vaccines, highlighting cross-dressing as a substantial contributor to their immunogenic profile. This revelation enriches the conceptual framework of vaccine immunology and provides a platform for innovation in next-generation vaccine strategies focused on eliciting robust cellular immunity.
As the field progresses, these mechanistic insights furnish a foundation for developing mRNA vaccines capable of eliciting comprehensive immune protection through multiple complementary antigen presentation pathways. Such advances hold promise for addressing emerging infectious diseases and improving therapeutic vaccine design for cancer and chronic infections globally.
Subject of Research:
Unconventional pathways of CD8+ T cell priming induced by mRNA vaccines involving dendritic cell cross-dressing and type I interferon-dependent mechanisms.
Article Title:
mRNA vaccines engage unconventional pathways in CD8+ T cell priming.
Article References:
Jo, S., Li, L., Thakur, C. et al. mRNA vaccines engage unconventional pathways in CD8+ T cell priming. Nature (2026). https://doi.org/10.1038/s41586-026-10353-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-026-10353-6
Tags: adaptive immunity mRNA vaccinesantigen cross-presentation MHC-ICD8 T cell activationcytotoxic T cell primingdendritic cell type 1 rolelipid nanoparticle vaccine mechanismmRNA vaccine immune responsemRNA-LNP vaccine technologyprotein antigen processingSARS-CoV-2 vaccine immunologyunconventional cytotoxic T lymphocytesvaccine-induced T cell responses
